Related Experiment Videos
PTCA update: is your patient now a candidate? Even complex multivessel lesions may succumb to balloon dilation
Insights
Percutaneous Transluminal Coronary Angioplasty (PTCA) is increasingly used for complex coronary artery disease, offering high success rates. While restenosis is a challenge, new devices may further improve outcomes for patients with coronary artery disease.
Area of Science:
- Cardiology
- Interventional Cardiology
- Vascular Medicine
Background:
- Percutaneous Transluminal Coronary Angioplasty (PTCA) indications are expanding.
- PTCA demonstrates high success and low complication rates in complex multivessel lesions.
- Dilation of chronic total occlusions is less successful but can relieve angina.
Purpose of the Study:
- To review the current indications and outcomes of PTCA.
- To discuss the role of PTCA in managing complex coronary artery disease, including chronic total occlusions and saphenous vein graft lesions.
- To highlight challenges such as restenosis and the potential of new devices.
Main Methods:
- Review of current literature and clinical practice regarding PTCA.
- Analysis of PTCA success rates, complication profiles, and long-term outcomes.
- Evaluation of PTCA in specific scenarios like chronic total occlusions, saphenous vein grafts, and acute myocardial infarction.
Main Results:
- PTCA is effective for complex multivessel lesions with high success and low complication rates.
- Dilation of chronic total occlusions is feasible, potentially relieving angina.
- Successful dilation and long-term patency can be achieved in occluded saphenous vein grafts, especially those <36 months old.
- Antithrombotic therapy (heparin during, aspirin after) is recommended to mitigate restenosis.
- PTCA serves as an adjunct in acute myocardial infarction when thrombolysis is ineffective or contraindicated.
Conclusions:
- PTCA is a valuable and evolving intervention for various coronary artery conditions.
- Restenosis remains a significant limitation, necessitating antithrombotic therapy.
- Investigational devices like atherectomy catheters, lasers, and stents show promise for expanding PTCA's role and improving patient outcomes.
Abstract:
Indications for PTCA continue to grow. In complex multivessel lesions, PTCA now has high primary success and low complication rates. Dilation of chronic total occlusions is less successful than in subtotal occlusions but may relieve angina in some patients. Occluded saphenous vein grafts can be dilated and long-term patency achieved--particularly in grafts implanted for less than 36 months. Restenosis remains a major drawback; antithrombotic therapy (with heparin during PTCA and aspirin thereafter) is recommended. PTCA is a useful adjunct in acute myocardial infarction when thrombolytic therapy fails or is contraindicated, or when significant luminal narrowing remains after thrombolysis. Investigational devices--atherectomy catheters, lasers or laser balloons, and intracoronary stents--may further expand the role of PTCA.